J. Safra Sarasin Holding AG Sells 438 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• J. Safra Sarasin Holding AG sold 438 shares of Regeneron Pharmaceuticals, reducing its holdings by 43.8% during the 2nd quarter, now owning 562 shares valued at $295,000.
• Analyst ratings for Regeneron have remained positive, with Guggenheim increasing the target price to $815.00 and multiple firms issuing 'buy' ratings, contributing to a consensus target price of $817.67.
• Regeneron reported a quarterly EPS of $12.89, exceeding analyst estimates by $4.46, and declared a quarterly dividend of $0.88, representing a yield of 0.6%.

J. Safra Sarasin Holding AG trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 43.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 562 shares of the biopharmaceutical company's stock after selling 438 shares during the quarter. J. Safra Sarasin Holding AG's holdings in Regeneron Pharmaceuticals were worth $295,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Marietta Wealth Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 30.2% during the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock worth $6,836,000 after purchasing an additional 2,501 shares during the last quarter. Sepio Capital LP raised its holdings in Regeneron Pharmaceuticals by 33.1% in the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company's stock worth $2,150,000 after purchasing an additional 842 shares in the last quarter. Founders Capital Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 7.0% during the second quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company's stock valued at $4,344,000 after buying an additional 538 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Regeneron Pharmaceuticals by 3.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after buying an additional 955 shares in the last quarter. Finally, PGGM Investments grew its position in shares of Regeneron Pharmaceuticals by 159.7% in the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company's stock worth $44,308,000 after buying an additional 51,900 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on REGN shares. Guggenheim increased their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Redburn Atlantic raised Regeneron Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, August 14th. Jefferies Financial Group upped their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a "buy" rating in a research report on Wednesday, August 27th. Canaccord Genuity Group reissued a "buy" rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Finally, Royal Bank Of Canada boosted their price target on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research note on Monday, August 4th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $600.00 on Monday. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,024.36. The stock's 50-day moving average price is $572.12 and its 200-day moving average price is $566.55. The stock has a market capitalization of $63.59 billion, a PE ratio of 15.12, a price-to-earnings-growth ratio of 1.92 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The company had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.Regeneron Pharmaceuticals's revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $11.56 earnings per share. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were paid a $0.88 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is currently 8.87%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.